We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Could Predict Future Risk of Developing Leukemia

By LabMedica International staff writers
Posted on 06 Jul 2022
Print article
Image: A blood test could predict risk of developing leukemia in elderly years in advance (Photo courtesy of University of Glasgow)
Image: A blood test could predict risk of developing leukemia in elderly years in advance (Photo courtesy of University of Glasgow)

Leukemia is often the result of the disruption to the fine balance in blood cell production where new cells are manufactured and old blood cells die. Now, a blood test could predict risk of developing leukemia in the elderly population years in advance by identifying changes in blood cell production, according to new research. By identifying those most at risk it should be possible to provide preventive or early treatment in the future to improve patient outcomes, experts say.

As we age, mutations in blood stem cells can mean that the altered cells can have a growth benefit over other blood cells and outnumber them in what is referred to as fitness advantage. Researchers from the University of Edinburgh (Scotland, UK) and University of Glasgow (Scotland, UK) investigated how changes in fitness advantage that occur in blood production might provide clues to risk of developing leukemia depending on the type of mutation that occurs.

The researchers measured changes in the blood samples of 83 older individuals of the Lothian Birth Cohorts, taken every three years over a 12-year period. The Lothian Birth Cohorts 1921 and 1936 are longitudinal studies of brain, cognitive and general ageing which have followed up individuals every three years between the ages of 70 and 82 for the 1921 cohort and the ages of 79 to 92 for 1936. The team then combined these complex genomic data with a machine-learning algorithm to link different mutations with different growth speeds of blood stem cells carrying these mutations.

The researchers found that specific mutations give distinct fitness advantages to stem cells measured in people without leukemia - this can then be used to forecast how quickly the mutated cells will grow, which determines leukemia risk. Further research is needed to validate these results in a larger population due to the limited sample size in the current study, according to the researchers.

“In knowing an individual patient’s risk of developing leukemia, clinicians can schedule shorter gaps between appointments in those most likely to develop the disease and provide early treatment, which is more likely to be successful,” said Dr. Kristina Kirschner, co-lead author and Senior Lecturer at University of Glasgow’s Institute of Cancer Sciences.

“To understand leukemia risk, we need to consider the balance between the different cells involved in blood cell production and how this balance changes as we grow older. By linking genomic data with machine learning we have been able to predict the future behaviour of blood cells based on the mutations they develop,” added Dr. Linus Schumacher, co-lead author and Chancellor’s Fellow at the Centre for Regenerative Medicine of the University of Edinburgh.

Related Links:
University of Edinburgh 
University of Glasgow 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.